Grace Therapeutics, Inc.
GRCE Nasdaq Pharmaceutical Preparations Financials FY2019โFY2026
Last close ยท Oct 23, 2026
$1.93
0.8%
Revenue
Total sales reported in the income statement.
โ
vs prior year
Operating margin
Operating income as a share of revenue.
โ
Net income
Profit after all expenses, interest and tax.
โ$7.8M
Free cash flow
Cash from operations minus capital spending.
โ
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$33.3M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$1.17 EPS (TTM)
What Grace Therapeutics, Inc. does
No business description yet.
- Legal name
- Grace Therapeutics, Inc.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K ยท Jun 18, 2026
- Accession ยท CIK
- 0001140361-26-025662
0001444192
Revenue and margins
Grace Therapeutics, Inc. had โ of revenue in fiscal 2026.
FY19
Revenue โ
FY20
Revenue โ
FY21
Revenue $0.2M
FY22
Revenue $100M
FY23
Revenue โ
FY24
Revenue โ
FY25
Revenue โ
FY26
Revenue โ
FY19
Gross โ
Operating โ
Net โ
FCF โ
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross 61.2%
Operating โ8,377.0%
Net โ10,039.8%
FCF โ
FY22
Gross 100.0%
Operating โ15.6%
Net โ9.8%
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ
Operating โ
Net โ
FCF โ
FY26
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY19
Net income โ$39.4M
FY20
Net income โ$25.5M
FY21
Net income โ$19.7M
FY22
Net income โ$9.8M
FY23
Net income โ$42.4M
FY24
Net income โ$12.9M
FY25
Net income โ$9.6M
FY26
Net income โ$7.8M
Q2 '24
Net income โ$3.3M
Q3 '24
Net income โ$2.4M
Q4 '24
Net income โ$3.2M
Q1 '25
Net income โ$2.6M
Q2 '25
Net income โ$3.4M
Q3 '25
Net income โ$4.2M
Q4 '25
Net income $0.6M
Q1 '26
Net income โ$3.4M
Q2 '26
Net income โ$0.9M
Q3 '26
Net income โ$2.3M
Q4 '26
Net income โ$1.2M
Q1 '27
Net income โ$15.8M
FY19
Diluted EPS โ$0.73
FY20
Diluted EPS โ$0.30
FY21
Diluted EPS โ$1.33
FY22
Diluted EPS โ$0.27
FY23
Diluted EPS โ$5.71
FY24
Diluted EPS โ$1.35
FY25
Diluted EPS โ$0.79
FY26
Diluted EPS โ$0.47
Q2 '24
Diluted EPS โ$0.43
Q3 '24
Diluted EPS โ$0.21
Q4 '24
Diluted EPS โ$0.17
Q1 '25
Diluted EPS โ$0.24
Q2 '25
Diluted EPS โ$0.30
Q3 '25
Diluted EPS โ$0.36
Q4 '25
Diluted EPS $0.11
Q1 '26
Diluted EPS โ$0.21
Q2 '26
Diluted EPS โ$0.06
Q3 '26
Diluted EPS โ$0.14
Q4 '26
Diluted EPS โ$0.06
Q1 '27
Diluted EPS โ$0.91
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY19
Return on capital โ
Return on equity โ356.4%
Return on assets โ106.7%
FY20
Return on capital โ
Return on equity โ212.3%
Return on assets โ85.4%
FY21
Return on capital โ
Return on equity โ57.3%
Return on assets โ46.1%
FY22
Return on capital โ
Return on equity โ12.0%
Return on assets โ10.3%
FY23
Return on capital โ
Return on equity โ48.2%
Return on assets โ40.8%
FY24
Return on capital โ
Return on equity โ19.8%
Return on assets โ16.9%
FY25
Return on capital โ
Return on equity โ14.9%
Return on assets โ13.2%
FY26
Return on capital โ
Return on equity โ11.9%
Return on assets โ11.2%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ in fiscal 2026, โ of revenue. Cash from operations minus capital spending.
FY19
Free cash flow โ
FY20
Free cash flow โ
FY21
Free cash flow โ
FY22
Free cash flow โ
FY23
Free cash flow โ
FY24
Free cash flow โ
FY25
Free cash flow โ
FY26
Free cash flow โ
FY19
Cash from operations โ
Capital spending โ
FY20
Cash from operations โ$23.0M
Capital spending โ
FY21
Cash from operations โ$14.3M
Capital spending โ
FY22
Cash from operations โ$17.2M
Capital spending โ
FY23
Cash from operations โ$15.9M
Capital spending โ
FY24
Cash from operations โ$12.3M
Capital spending โ
FY25
Cash from operations โ$14.9M
Capital spending โ
FY26
Cash from operations โ$8.9M
Capital spending โ
Cash from operations
Capital spending
Q2 '24
Cash from operations โ$2.1M
Capital spending โ
Q3 '24
Cash from operations โ$1.9M
Capital spending โ
Q4 '24
Cash from operations โ$2.1M
Capital spending โ
Q1 '25
Cash from operations โ$3.6M
Capital spending โ
Q2 '25
Cash from operations โ$4.2M
Capital spending โ
Q3 '25
Cash from operations โ$4.1M
Capital spending โ
Q4 '25
Cash from operations โ$3.0M
Capital spending โ
Q1 '26
Cash from operations โ$1.8M
Capital spending โ
Q2 '26
Cash from operations โ$3.1M
Capital spending โ
Q3 '26
Cash from operations โ$2.2M
Capital spending โ
Q4 '26
Cash from operations โ$1.7M
Capital spending โ
Q1 '27
Cash from operations โ$3.2M
Capital spending โ
Cash from operations
Capital spending
Dividends, buybacks and share count
Grace Therapeutics, Inc. returned โ to shareholders in fiscal 2026. The diluted share count rose 36.6%.
FY19
Dividends โ
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
FY26
Dividends โ
Buybacks โ
Dividends
Buybacks
FY19
Diluted shares 0.05B
FY20
Diluted shares 0.08B
FY21
Diluted shares 0.01B
FY22
Diluted shares 0.04B
FY23
Diluted shares 0.01B
FY24
Diluted shares 0.01B
FY25
Diluted shares 0.01B
FY26
Diluted shares 0.02B
Balance sheet
Cash, debt and the ratios that show how comfortably Grace Therapeutics, Inc. can carry it.
FY19
Cash $25.8M
Debt โ
FY20
Cash $14.2M
Debt โ
FY21
Cash $60.7M
Debt โ
FY22
Cash $43.7M
Debt โ
FY23
Cash $27.9M
Debt โ
FY24
Cash $23.0M
Debt โ
FY25
Cash $22.1M
Debt โ
FY26
Cash $17.0M
Debt โ
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $43.7M | $27.9M | $23.0M | $22.1M | $17.0M |
| Current ratio | 13.9x | 8.6x | 14.3x | 11.8x | 8.1x |
| Quick ratio | 13.9x | 8.6x | 14.3x | 11.8x | 8.1x |
| Total assets | $129M | $79.1M | $73.3M | $72.0M | $66.7M |
| Total liabilities | $20.4M | $11.2M | $11.6M | $5.4M | $2.8M |
| Shareholders' equity | $108M | $68.0M | $61.7M | $66.6M | $63.9M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 1 | โ / 6 | โ / 6 | 3 / 8 | โ / 6 | โ / 6 | โ / 6 | โ / 6 |
| Accruals ratio | โ | โ8.6% | โ12.6% | 7.8% | โ25.5% | โ0.7% | 7.3% | 1.6% |
| Altman Z'' | โ12.18 | โ20.65 | 5.59 | 2.97 | โ4.06 | โ2.96 | 3.34 | 13.53 |
8 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | โ | โ | $0.2M | $100M | โ | โ | โ | โ |
| Gross profit | โ | โ | $0.1M | $100M | โ | โ | โ | โ |
| Research and development | $29.4M | $16.0M | $4.2M | $5.6M | $10.0M | $4.7M | $9.5M | $2.4M |
| Operating income | โ$34.4M | โ$24.4M | โ$16.4M | โ$15.6M | โ$52.2M | โ$12.9M | โ$16.7M | โ$11.1M |
| Pretax income | โ$39.4M | โ$25.5M | โ$19.7M | โ$10.5M | โ$52.0M | โ$14.7M | โ$12.8M | โ$9.5M |
| Income tax | $0.0M | $0.0M | $0.0M | โ$0.6M | โ$9.5M | โ$1.8M | โ$3.2M | โ$1.7M |
| Net income | โ$39.4M | โ$25.5M | โ$19.7M | โ$9.8M | โ$42.4M | โ$12.9M | โ$9.6M | โ$7.8M |
| Diluted EPS | โ$0.73 | โ$0.30 | โ$1.33 | โ$0.27 | โ$5.71 | โ$1.35 | โ$0.79 | โ$0.47 |
| Diluted shares | 0.05B | 0.08B | 0.01B | 0.04B | 0.01B | 0.01B | 0.01B | 0.02B |
| Cash flow | ||||||||
| Cash from operations | โ | โ$23.0M | โ$14.3M | โ$17.2M | โ$15.9M | โ$12.3M | โ$14.9M | โ$8.9M |
| Depreciation and amortization | $0.4M | $0.4M | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | โ | $2.0M | $1.2M | $1.3M | $1.8M | $0.9M | $0.7M | $0.8M |
| Balance sheet | ||||||||
| Cash and short-term investments | $25.8M | $14.2M | $60.7M | $43.7M | $27.9M | $23.0M | $22.1M | $17.0M |
| Current assets | $28.0M | $18.5M | $62.4M | $45.3M | $29.3M | $24.0M | $22.7M | $17.4M |
| Current liabilities | $13.7M | $7.4M | $1.6M | $3.3M | $3.4M | $1.7M | $1.9M | $2.1M |
| Property and equipment, net | $2.1M | $1.9M | โ | $20.9M | $0.1M | $0.0M | $0.0M | $0.0M |
| Goodwill | โ | โ | โ | $13.0M | $8.1M | $8.1M | $8.1M | $8.1M |
| Intangible assets | $6.4M | $4.2M | $0.0M | $69.8M | $41.1M | $41.1M | $41.1M | $41.1M |
| Total assets | $36.9M | $22.9M | $62.5M | $129M | $79.1M | $73.3M | $72.0M | $66.7M |
| Total liabilities | $25.9M | $9.9M | $6.8M | $20.4M | $11.2M | $11.6M | $5.4M | $2.8M |
| Preferred stock | โ | โ | โ | โ | โ | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $11.0M | $13.0M | $55.7M | $108M | $68.0M | $61.7M | $66.6M | $63.9M |
| Margins | ||||||||
| Gross margin | โ | โ | 61.2% | 100.0% | โ | โ | โ | โ |
| Operating margin | โ | โ | โ8,377.0% | โ15.6% | โ | โ | โ | โ |
| EBITDA margin | โ | โ | โ8,304.1% | โ15.6% | โ | โ | โ | โ |
| Net margin | โ | โ | โ10,039.8% | โ9.8% | โ | โ | โ | โ |
| Returns | ||||||||
| Return on capital employed | โ148.1% | โ158.1% | โ27.0% | โ12.4% | โ68.9% | โ17.9% | โ23.8% | โ17.2% |
| Return on equity | โ356.4% | โ212.3% | โ57.3% | โ12.0% | โ48.2% | โ19.8% | โ14.9% | โ11.9% |
| Return on assets | โ106.7% | โ85.4% | โ46.1% | โ10.3% | โ40.8% | โ16.9% | โ13.2% | โ11.2% |
| Return on tangible equity | โ844.9% | โ291.6% | โ35.4% | โ38.5% | โ227.0% | โ103.0% | โ55.2% | โ53.3% |
| Growth | ||||||||
| Revenue growth | โ | โ | โ | 50,920.4% | โ | โ | โ | โ |
| Share count change | โ | 55.8% | โ82.5% | 148.5% | โ79.8% | 28.2% | 26.8% | 36.6% |
| Financial health | ||||||||
| Current ratio | 2.0x | 2.5x | 39.5x | 13.9x | 8.6x | 14.3x | 11.8x | 8.1x |
| Quick ratio | 2.0x | 2.5x | 39.5x | 13.9x | 8.6x | 14.3x | 11.8x | 8.1x |
| Capital allocation | ||||||||
| Stock comp / revenue | โ | โ | 599.0% | 1.3% | โ | โ | โ | โ |
| Quality scores | ||||||||
| Piotroski F-score | โ | โ | โ | 3.0 | โ | โ | โ | โ |
| Altman Z'' | โ12.2 | โ20.6 | 5.6 | 3.0 | โ4.1 | โ3.0 | 3.3 | 13.5 |
| Accruals ratio | โ | โ8.6% | โ12.6% | 7.8% | โ25.5% | โ0.7% | 7.3% | 1.6% |
Source: SEC EDGAR XBRL filings (CIK 0001444192). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.